Value2022202320242025TTMSelling/general/admin expenses621 M763.2 M766.8 M746.3 M758.6 MResearch & development190.5 M246.8 M218.7 M186.2 M177.9 MOperating income843.7 M139.1 M-1.96 B-919.2 M-983.6 MNon-Operating Income, Total-8.1 M-20.6 M-7.1 M-5.8 M-1 MInterest expense, net of interest capitalized2.1 M3.3 M163.5 M177.6 M188.7 MNon-Operating Income, excl. Interest Expenses-2.1 M-3.3 M-163.5 M-177.6 M-188.7 MUnusual income/expense-8.1 M-20.6 M-7.1 M-5.8 M-1 MPretax income735.9 M-29.1 M-2.13 B-1.11 B-1.18 BEquity in earnings-5.8 M-3.6 M700 K2.5 M—Taxes187.2 M-19 M-79.5 M24.1 M32.5 MNon-controlling/minority interest—————After tax other income/expense—————Net income before discontinued operations548.7 M-10.1 M-2.05 B-1.13 B-1.21 BDiscontinued operations—————Net income548.7 M-10.1 M-2.05 B-1.13 B-1.21 BDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders548.7 M-10.1 M-2.05 B-1.13 B-1.21 BBasic earnings per share (Basic EPS)9.66-0.15-30.54-16.69-17.85Diluted earnings per share (Diluted EPS)9.56-0.15-30.54-16.69-17.85Average basic shares outstanding56.8 M66.8 M67.2 M67.8 M—Diluted shares outstanding57.4 M66.8 M67.2 M67.8 M—EBITDA1.89 B1.52 B-558 M702.4 M-1.13 BEBIT1.56 B1.06 B-1.01 B260.4 M-1.58 BCost of revenue1.33 B1.5 B1.5 B1.46 B1.46 BOther cost of goods sold1.33 B1.5 B1.5 B1.46 B1.46 BDepreciation & amortization (cash flow)283.6 M457.2 M453.4 M442 M447.8 M
QuidelOrtho Corporation - Common Stock
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.